Cronos Group Inc
TSX:CRON

Watchlist Manager
Cronos Group Inc Logo
Cronos Group Inc
TSX:CRON
Watchlist
Price: 3.29 CAD -5.19% Market Closed
Market Cap: 1.3B CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CRON stock under the Base Case scenario is 0.3 CAD. Compared to the current market price of 3.29 CAD, Cronos Group Inc is Overvalued by 91%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRON Relative Value
Base Case
0.3 CAD
Overvaluation 91%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7
P/S
P/S
Price to Sales
7
vs History
82
vs Industry
22
Median 3Y
8.8
Median 5Y
11.2
Industry
2.7
Forward
6.1
More Details
49.4
P/E
P/E
Price to Earnings
49.4
vs History
0
vs Industry
28
Median 3Y
-5.7
Median 5Y
-5.5
Industry
22.2
Forward
-53.6
More Details
45.6
P/OCF
P/OCF
Price to OCF
45.6
vs History
9
vs Industry
11
Median 3Y
-7
Median 5Y
-9.4
Industry
17.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
3
Median 3Y
-9
Median 5Y
-10.2
Industry
23.7
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
44
vs Industry
69
Median 3Y
0.7
Median 5Y
0.9
Industry
2.3
More Details
0.6
EV/S
EV/S
Enterprise Value to Sales
0.6
vs History
53
vs Industry
81
Median 3Y
-0.6
Median 5Y
1.2
Industry
2.8
Forward
0.5
More Details
1.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.9
vs History
19
vs Industry
41
Median 3Y
-3
Median 5Y
-8.5
Industry
5.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
50
Median 3Y
0.8
Median 5Y
-1
Industry
13.3
Forward
-58
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
49
Median 3Y
0.7
Median 5Y
-0.9
Industry
16.5
Forward
-2.6
More Details
4
EV/OCF
EV/OCF
Enterprise Value to OCF
4
vs History
4
vs Industry
18
Median 3Y
0.5
Median 5Y
-2.2
Industry
15.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
35
Median 3Y
0.7
Median 5Y
-2.6
Industry
17.9
More Details
0.2
EV/IC
EV/IC
Enterprise Value to IC
0.2
vs History
47
vs Industry
81
Median 3Y
-0.2
Median 5Y
0.4
Industry
2
More Details

Multiples Across Competitors

CRON Competitors Multiples
Cronos Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cronos Group Inc
TSX:CRON
1.3B CAD 7 49.4 -3.1 -2
US
Eli Lilly and Co
NYSE:LLY
663.9B USD 12.5 48.1 28.5 31
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
424.9B USD 4.7 18.8 14.3 18.8
CH
Roche Holding AG
SIX:ROG
203.6B CHF 3.4 24.6 9.3 10.8
UK
AstraZeneca PLC
LSE:AZN
179.8B GBP 4.3 29.4 113.3 169.4
CH
Novartis AG
SIX:NOVN
192.2B CHF 4.3 17.5 10.5 13.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13 9.5 10.6
US
Merck & Co Inc
NYSE:MRK
211.9B USD 3.3 12.9 8.3 9.9
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
142.9B USD 2.2 13.3 7.5 10.3
P/E Multiple
Earnings Growth PEG
CA
Cronos Group Inc
TSX:CRON
Average P/E: 25.2
49.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.8
27%
0.7
CH
Roche Holding AG
SIX:ROG
24.6
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.4
36%
0.8
CH
Novartis AG
SIX:NOVN
17.5
16%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13
18%
0.7
US
Merck & Co Inc
NYSE:MRK
12.9
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.3
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Cronos Group Inc
TSX:CRON
Average EV/EBITDA: 433.9
Negative Multiple: -3.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.5
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.3
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.3
10%
11.3
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
13%
0.7
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Cronos Group Inc
TSX:CRON
Average EV/EBIT: 1 870.9
Negative Multiple: -2 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.8
14%
1.3
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.4
23%
7.4
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.9
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
9%
1.1

See Also

Summary
CRON intrinsic value, competitors valuation, and company profile.
DCF Valuation
CRON stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CRON stock valuation using valuation multiples.
Wall Street Estimates
CRON price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CRON stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 275,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.